PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Targeted therapy - Market size and forecast 2018-2023 • Chemotherapy - Market size and forecast 2018-2023 • Immunotherapy - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS • Emergence of pipeline molecules • Development of diagnostic tests and predictive markers • Increasing research in regenerative medicines PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Boehringer Ingelheim International GmbH • Bristol-Myers Squibb Co. • F. Hoffmann-La Roche Ltd. • Merck & Co. Inc. • Mylan NV • Novartis AG • Otsuka Holdings Co. Ltd. • Pfizer Inc. • Takeda Pharmaceutical Co. Ltd. • Teva Pharmaceutical Industries Ltd. PART 13: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 14: EXPLORE TECHNAVIO   Exhibit 01: Vendors: Key offerings Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Immunotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Immunotherapy - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Boehringer Ingelheim International GmbH - Vendor overview Exhibit 51: Boehringer Ingelheim International GmbH - Product segments Exhibit 52: Boehringer Ingelheim International GmbH - Organizational developments Exhibit 53: Boehringer Ingelheim International GmbH - Geographic focus Exhibit 54: Boehringer Ingelheim International GmbH - Segment focus Exhibit 55: Boehringer Ingelheim International GmbH - Key offerings Exhibit 56: Boehringer Ingelheim International GmbH - Key customers Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview Exhibit 58: Bristol-Myers Squibb Co. - Product segments Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus Exhibit 61: Bristol-Myers Squibb Co. - Key offerings Exhibit 62: Bristol-Myers Squibb Co. - Key customers Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 64: F. Hoffmann-La Roche Ltd. - Product segments Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 69: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 70: Merck & Co. Inc. - Vendor overview Exhibit 71: Merck & Co. Inc. - Product segments Exhibit 72: Merck & Co. Inc. - Organizational developments Exhibit 73: Merck & Co. Inc. - Geographic focus Exhibit 74: Merck & Co. Inc. - Segment focus Exhibit 75: Merck & Co. Inc. - Key offerings Exhibit 76: Merck & Co. Inc. - Key customers Exhibit 77: Mylan NV - Vendor overview Exhibit 78: Mylan NV - Product segments Exhibit 79: Mylan NV - Organizational developments Exhibit 80: Mylan NV - Geographic focus Exhibit 81: Mylan NV - Segment focus Exhibit 82: Mylan NV - Key offerings Exhibit 83: Mylan NV - Key customers Exhibit 84: Novartis AG - Vendor overview Exhibit 85: Novartis AG - Product segments Exhibit 86: Novartis AG - Organizational developments Exhibit 87: Novartis AG - Geographic focus Exhibit 88: Novartis AG - Segment focus Exhibit 89: Novartis AG - Key offerings Exhibit 90: Novartis AG - Key customers Exhibit 91: Otsuka Holdings Co. Ltd. - Vendor overview Exhibit 92: Otsuka Holdings Co. Ltd. - Product segments Exhibit 93: Otsuka Holdings Co. Ltd. - Organizational developments Exhibit 94: Otsuka Holdings Co. Ltd. - Geographic focus Exhibit 95: Otsuka Holdings Co. Ltd. - Segment focus Exhibit 96: Otsuka Holdings Co. Ltd. - Key offerings Exhibit 97: Otsuka Holdings Co. Ltd. - Key customers Exhibit 98: Pfizer Inc. - Vendor overview Exhibit 99: Pfizer Inc. - Product segments Exhibit 100: Pfizer Inc. - Organizational developments Exhibit 101: Pfizer Inc. - Geographic focus Exhibit 102: Pfizer Inc. - Segment focus Exhibit 103: Pfizer Inc. - Key offerings Exhibit 104: Pfizer Inc. - Key customers Exhibit 105: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 106: Takeda Pharmaceutical Co. Ltd. - Product segments Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 111: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 112: Teva Pharmaceutical Industries Ltd. - Product segments Exhibit 113: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 114: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 115 Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 116: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 117: Validation techniques employed for market sizing Exhibit 118: Definition of market positioning of vendors

Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.